natgillin/translations-raw huggingface dataset:
- diuretics (used to treat high blood pressure or excessive fluid retention), - glucagon (pancreas hormone used to treat severe hypoglycaemia), - isoniazid (used to treat tuberculosis), - oestrogens and progestogens (such as in the contraceptive pill used for birth control), - phenothiazine derivatives (used to treat psychiatric disorders), - somatropin (growth hormone), - sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma), - thyroid hormones (used to treat thyroid gland disorders), - atypical antipsychotic medicines (such as clozapine, olanzapine), - protease inhibitors (used to treat HIV). 
- kortikosteroidi (na primer "kortizon", uporabljajo se za zdravljenje vnetja), - danazol (zdravilo, ki deluje na ovulacijo), - diazoksid (uporablja se za zdravljenje visokega krvnega tlaka), - diuretiki (uporabljajo se za zdravljenje visokega krvnega tlaka ali za prekomerno zadrževanje tekočin), - glukagon (hormon, ki ga izloča trebušna slinavka, uporablja pa se za zdravljenje hude hipoglikemije), - izoniazid (uporablja se za zdravljenje tuberkuloze), - estrogeni in progestogeni (na primer kontracepcijske tablete, uporabljajo se za načrtovanje rojstva),
Step 11: 
Korak 11:
Your blood sugar levels may either rise or fall if you drink alcohol. 
Če pijete alkohol, se vam lahko krvni sladkor zviša ali zniža.
• Pull off the paper tab from the outer needle shield. 
Potegnite papirni pokrovček z zaščite zunanje igle.
Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. 
Če opazite, da se urejenost vašega krvnega sladkorja nepričakovano poslabša, vedno uporabite nov vložek.
Although ABASAGLAR contains the same active substance as Toujeo (insulin glargine 300 units/mL), these medicines are not interchangeable. 
Čeprav zdravilo ABASAGLAR vsebuje enako učinkovino kot zdravilo Toujeo (insulin glargin
ABASAGLAR KwikPen (“Pen”) is a disposable pen containing 300 units (3 mL) of insulin glargine. 
Peresnik ABASAGLAR KwikPen (“peresnik”) je peresnik za enkratno uporabo, ki vsebuje 300 enot
General information about the safe and effective use of your pen • Keep your pen and needles out of the sight and reach of children. 
Splošne informacije o varni in učinkoviti uporabi vašega peresnika
• Replace the pen cap by lining up the cap clip with the dose indicator and pushing straight on. 
Znova namestite pokrovček peresnika, tako da poravnate sponko pokrovčka s kazalnikom odmerkov in pokrovček potisnete naravnost na peresnik.
Lipoatrophy 
Retinopatija
You must always check the insulin label before each injection to avoid mix-ups between ABASAGLAR and other insulins. 
Da bi se izognili zamenjavi med zdravilom ABASAGLAR in drugimi insulini, vedno pred vsakim injiciranjem preverite nalepko insulina.
How to store ABASAGLAR 
Shranjevanje zdravila ABASAGLAR
The cartridge is sealed in a disposable pen injector. 
Vložek je zaprt v injektorju v obliki peresnika za večkratno uporabo.
Visual impairment 
Ohišje peresnika
Posology 
Vložek
When given intravenously the elimination half-life of insulin glargine and human insulin were comparable. 
Izločanje Razpolovni čas izločanja insulina glargin po intravenski uporabi je primerljiv tistemu pri humanem insulinu.
Plasma trough levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing. 
»Najnižje« plazemske ravni insulina glargin in njegovih glavnih metabolitov, M1 in M2, so bile izmerjene pri otrocih, zdravljenih z insulinom glargin
Always use a new cartridge if you notice that your blood sugar control is unexpectedly getting worse. 
Če opazite, da se urejenost vašega krvnega sladkorja nepričakovano poslabša, vedno uporabite nov peresnik.
The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration. 
Dolgotrajnejše delovanje subkutanega insulina glargin je neposredno povezano z njegovo počasnejšo absorpcijo in podpira uporabo enkrat na dan. Časovni potek delovanja insulina in insulinskih analogov, kakršen je insulin glargin, se lahko zelo razlikuje tako med posamezniki kot pri eni in isti osebi.
Do not use ABASAGLAR if you notice particles in it. Only use ABASAGLAR if the solution is clear, colourless and water like. 
Zdravilo ABASAGLAR uporabite le, če je raztopina bistra, brezbarvna in podobna vodi.
- all other medicines to treat diabetes, - angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure), - disopyramide (used to treat certain heart conditions), - fluoxetine (used to treat depression), - fibrates (used to lower high levels of blood lipids), - monoamine oxidase (MAO) inhibitors (used to treat depression), - pentoxifylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever), - somatostatin analogues (such as octreotide, used to treat an uncommon condition in which you make too much growth hormone), - sulphonamide antibiotics. 
- fluoksetin (uporablja se za zdravljenje depresije), - fibrati (uporabljajo se za zniževanje visokih koncentracij krvnih lipidov), - zaviralci monoaminooksidaze (MAO) (uporabljajo se za zdravljenje depresije), - pentoksifilin, propoksifen, salicilati (na primer acetilsalicilna kislina, uporabljajo se za lajšanje bolečine in znižanje zvišane telesne temperature),
- correct storage of your insulin while travelling, - timing of meals and insulin administration while travelling, - the possible effects of changing to different time zones, - possible new health risks in the countries to be visited, - what you should do in emergency situations when you feel unwell or become ill. 
- časovni razpored obrokov in dajanje insulina med potovanjem, - možni vplivi spremembe časovnih pasov,
ABASAGLAR 100 units/mL injection insulin glargine 
ABASAGLAR 100 enot /ml injekcija insulin glargin subkutana uporaba
These include: - change in the injection area, - improved insulin sensitivity (e.g., by removal of stress factors), - unaccustomed, increased or prolonged physical activity, - intercurrent illness (e.g. vomiting, diarrhoea), - inadequate food intake, - missed meals, - alcohol consumption, - certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency), - concomitant treatment with certain other medicinal products. 
- boljša občutljivost za insulin (npr. zaradi odprave dejavnikov stresa), - nevajena, večja ali dolgotrajnejša telesna dejavnost, - sočasna bolezen (npr. bruhanje, driska),
The ABASAGLAR cartridges are to be used only in Lilly insulin pens to ensure you get the correct dose. 
Da boste zagotovo prejeli pravilen odmerek, vložke ABASAGLAR uporabljajte le v insulinskih peresnikih Lilly.
KwikPen Parts 
Deli peresnika KwikPen
carbohydrates), - you lose carbohydrates due to vomiting or diarrhoea, - you drink alcohol, particularly if you are not eating much, - you are doing more exercise than usual or a different type of physical activity, - you are recovering from an injury or operation or other stress, - you are recovering from an illness or from fever, - you are taking or have stopped taking certain other medicines (see section 2, "Other medicines and ABASAGLAR"). 
- okrevate po bolezni ali po vročini, - uporabljate ali ste prenehali uporabljati določena druga zdravila (glejte poglavje 2, "Druga zdravila in zdravilo ABASAGLAR").
Insulin label must always be checked before each injection to avoid medication errors between ABASAGLAR and other insulins. 
Da bi se izognili napakam zdravljenja zaradi zamenjave med zdravilom ABASAGLAR in drugimi insulini, je potrebno nalepko insulina vedno preveriti pred vsakim injiciranjem.
Speak to a doctor immediately if you are not able to control the hypoglycaemia or if it recurs. 
Če hipoglikemije ne morete obvladati ali se ponavlja, se takoj pogovorite z zdravnikom.
EU/1/14/944/008 5 pens EU/1/14/944/013 5 pens 
EU/1/14/944/003 5 vložkov EU/1/14/944/009 10 vložkov
- corticosteroids (such as "cortisone" used to treat inflammation), - danazol (medicine acting on ovulation), - diazoxide (used to treat high blood pressure), 
- kortikosteroidi (na primer "kortizon", uporabljajo se za zdravljenje vnetja), - danazol (zdravilo, ki deluje na ovulacijo), - diazoksid (uporablja se za zdravljenje visokega krvnega tlaka), - diuretiki (uporabljajo se za zdravljenje visokega krvnega tlaka ali za prekomerno zadrževanje tekočin), - glukagon (hormon, ki ga izloča trebušna slinavka, uporablja pa se za zdravljenje hude hipoglikemije), - izoniazid (uporablja se za zdravljenje tuberkuloze),
Unopened cartridges 
Neuporabljeni peresniki
Retinopathy 
ZDRAVILA
Examples include: - you have not injected your insulin or not injected enough, or if it has become less effective, for example through incorrect storage, - your insulin pen does not work properly, - you are doing less exercise than usual, you are under stress (emotional distress, excitement), or you have an injury, operation, infection or fever, - you are taking or have taken certain other medicines (see section 2, "Other medicines and 
- insulina niste injicirali, ga niste injicirali dovolj ali je postal manj učinkovit, na primer zaradi nepravilnega shranjevanja, - vaš insulinski peresnik ne deluje pravilno,
- A drop of insulin at the needle tip is normal. 
- Kapljica insulina na konici igle je običajen pojav in ne vpliva na vaš odmerek.
See the box at the end of this leaflet for further information. 
Dodatne informacije najdete v okviru na koncu tega navodila za uporabo.
5sec 
V
Pen Cap 
Sponka pokrovčka
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. 
diazoksid, diuretiki, glukagon, izoniazid, estrogeni, progestogeni, fenotiazinski derivati, somatropin,
You should contact your doctor for advice on driving if: - you have frequent episodes of hypoglycaemia, - the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent. 
- imate pogoste hipoglikemije, - so prvi opozorilni znaki hipoglikemije šibki ali jih sploh nimate.
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen 
ABASAGLAR 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
ABASAGLAR 100 units/mL solution for injection in a cartridge insulin glargine 
ABASAGLAR 100 enot/ml raztopina za injiciranje v vložku insulin glargin
ABASAGLAR 100 units/mL solution for injection in a cartridge and pre-filled pen 
ABASAGLAR 100 enot/ml raztopina za injiciranje v vložku in napolnjenem injekcijskem peresniku
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS CARTRIDGE LABEL 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
ABASAGLAR 100 units/mL solution for injection in a cartridge 
ABASAGLAR 100 enot/ml raztopina za injiciranje v vložku
In-use pens 
Pokrovček peresnika
Zinc oxide 
Kazalnik odmerkov
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS LABEL TEXT -KwikPen 
OVOJNINAH BESEDILO NA NALEPKI -KwikPen
These include: - change in the injection area, - improved insulin sensitivity (e.g., by removal of stress factors), 
Ti so: - sprememba predela injiciranja,
Instructions for use KwikPen ABASAGLAR 100 units/mL solution for injection in a pre-filled pen Insulin glargine 
Navodilo za uporabo ABASAGLAR 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku insulin glargin
ABASAGLAR 100 units/mL solution for injection in a pre-filled pen insulin glargine 
ABASAGLAR 100 enot/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku insulin glargin
- beta-blockers (used to treat high blood pressure), - clonidine (used to treat high blood pressure), - lithium salts (used to treat psychiatric disorders). 
- klonidin (uporablja se za zdravljenje visokega krvnega tlaka),
Solution for injection (injection). 
raztopina za injiciranje (injekcija) Bistra, brezbarvna raztopina.
EU/1/14/944/003 5 cartridges EU/1/14/944/009 10 cartridges 
EU/1/14/944/008 5 peresnikov EU/1/14/944/013 5 peresnikov
EU/1/14/944/007 5 pens EU/1/14/944/012 5 pens 
EU/1/14/944/007 5 peresnikov EU/1/14/944/012 5 peresnikov
• Hold your pen with the needle pointing up. 
• Še naprej držite vaš injekcijski peresnik tako, da je igla obrnjena navzgor.
Dose Indicator 
Držalo vložka Oznaka
After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of microprecipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/time profile with a prolonged duration of action. 
Nastanejo mikroprecipitati, iz katerih se trajno sprošča majhna količina insulina glargin.
Troubleshooting 
Odmerjanje
Package leaflet: Information for the user ABASAGLAR 100 units/mL solution for injection in a cartridge insulin glargine 
Navodilo za uporabo ABASAGLAR 100 enot/ml raztopina za injiciranje v vložku insulin glargin
Not yet known1 
Še ni znano1
Tel. +44 (0)20 7418 8427 E-mail: press@ema.europa.eu 
Tel: +44 (0)20 7418 8427 E-pošta: press@ema.europa.eu
16 January 2014 EMA/35464/2014 
16. januar 2014 EMA/35464/2014
Contact our press officers Monika Benstetter or Martin Harvey 
Stopite v stik z našimi tiskovnimi predstavniki Monika Benstetter ali Martin Harvey
The review of combined hormonal contraceptives was initiated in February 2013 at the request of France, under Article 31 of Directive 2001/83/EC. 
Pregled kombiniranih hormonskih kontraceptivov je bil sprožen februarja 2013 na zahtevo Francije v skladu s členom 31 Direktive 2001/83/ES.
• If you have any questions or concerns, speak with your doctor, pharmacist or nurse. 
• Če imate kakršna koli vprašanja ali pomisleke, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
The classification as ‘second, third or fourth generation' is however not science-based and not standardised, and may differ between institutions and publications. 
Vendar pa opredelitev „druga, tretja ali četrta generacija“ ni znanstveno utemeljena in standardizirana, tako da se lahko med ustanovami in publikacijami razlikuje.
The CHMP opinion was forwarded to the European Commission, which issued a final decision on 16 January 2014. 
Odbor CHMP je mnenje posredoval Evropski komisiji, ki je dne 16. januarja 2014 izdala končni sklep.
But it is important that you are aware of the risk of blood clots associated with these medicines, even though it is very low. 
Pomembno pa je, da se zavedate tveganja za krvne strdke, povezanega s temi zdravili, čeprav je zelo majhno.
If you develop any of these signs and symptoms you should seek medical advice immediately. 
Če opazite katerega koli od teh znakov in simptomov, se takoj posvetujte z zdravnikom.
The review has reinforced the importance of ensuring that clear and up-to-date information is provided to women who use these medicines and to the healthcare professionals giving advice and clinical care. 
Pregled je potrdil, kako pomembno je, da se zagotovijo jasne in posodobljene informacije za ženske, ki uporabljajo ta zdravila, in zdravstvene delavce, ki jim svetujejo ter zagotavljajo klinično oskrbo.
• You should also be aware of the factors that increase your risk of a clot and be aware of how these may change over time. 
• Prav tako morate poznati dejavnike, ki povečajo tveganje za strdke, in vedeti, da se ti sčasoma lahko spremenijo.
Risk of developing a blood clot (VTE) in a year Women not using a combined hormonal pill/patch/ring and are not pregnant 
Tveganje za nastanek krvnega strdka (VTE) v enem letu Ženske, ki ne uporabljajo kombinirane hormonske tabletke/obliža/obročka in niso noseče
• Because a woman's individual risk factors will change over time, there is a need to regularly reassess the suitability of her contraceptive. 
• Ker se individualni dejavniki tveganja pri ženski sčasoma spremenijo, je treba redno ocenjevati primernost predpisanega kontraceptiva.
It is important that women are made aware of the risk of VTE and its signs and symptoms, and that doctors take into consideration a woman's individual risk factors when prescribing a contraceptive. 
Pomembno je, da so ženske seznanjene s tveganjem za VTE, njenimi znaki in simptomi, ter da zdravniki ob predpisovanju kontraceptivov upoštevajo individualne dejavnike tveganja pri vsaki ženski.
These are sometimes referred to as ‘third generation' or ‘fourth generation' contraceptives and are available as pills, skin patches and vaginal rings. 
Tem kontraceptivom včasih pravimo „tretja generacija“ ali „četrta generacija“ kontraceptivov, na voljo pa so v obliki tabletk, kožnih obližev in vaginalnih obročkov.
• When taking CHCs, you should be alert for the signs and symptoms of blood clots, which may include severe pain or swelling in the legs, sudden unexplained breathlessness, rapid breathing or cough, chest pain, and weakness or numbness of the face, arm or leg. 
• Med jemanjem kombiniranih hormonskih kontraceptivov bodite pozorni na znake in simptome krvnih strdkov, ki lahko vključujejo hude bolečine v nogah ali otekanje nog, nenadno nepojasnjeno zasoplost, hitro dihanje ali kašelj, bolečine v prsnem košu in šibkost ali omrtvičenost obraza, roke ali noge.
Risk factors include being very overweight, increasing age, having a member of your family who has had a blood clot at a relatively young age (e.g. below 50), having migraine or being immobilised for a long time (e.g. because of an illness or injury). 
Med dejavnike tveganja spadajo zelo povečana telesna masa, višja starost, dejstvo, da ima član vaše družine krvne strdke pri relativno nizki starosti (npr. pred 50. letom), migrene in daljša imobilizacija (npr. zaradi bolezni ali poškodbe).
1 Further studies are ongoing or planned to collect sufficient data to estimate the risk for these products. 
1 Dodatne študije, v katerih bodo zbrali zadostne podatke za oceno tveganja pri teh zdravilih, že potekajo ali pa so predvidene.
This risk is very low and there is no evidence for a difference in the level of risk between products depending on the type of progestogen. 
Tveganje je zelo majhno, poleg tega pa ni dokazov o tem, da bi se stopnja tveganja med zdravili razlikovala glede na vrsto progestogena.
With the exception of Zoely (nomegestrol acetate/estradiol), Ioa (nomegestrol acetate/estradiol) and Evra (norelgestromin/ethinylestradiol), which have been authorised centrally through the EMA, all other combined contraceptives in the EU have been authorised via national procedures. 
Razen kontraceptivov Zoely (nomegestrolacetat/estradiol), Ioa (nomegestrolacetat/estradiol) in Evra (norelgestromin/etinilestradiol), ki so bili odobreni po centraliziranem postopku, ki ga vodi Evropska agencija za zdravila, so bili vsi drugi kombinirani kontraceptivi v EU odobreni po nacionalnih postopkih.
CHCs are contraindicated if a woman has one serious or multiple risk factors that put her at high risk of blood clots. 
Kombinirani hormonski kontraceptivi so kontraindicirani, če ima ženska enega resnega ali več dejavnikov tveganja, zaradi katerih pri njej obstaja veliko tveganje za krvne strdke.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of CHCs in preventing unwanted pregnancies continue to outweigh their risks, and that the well-known risk of VTE with all CHCs is small. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Evropski agenciji za zdravila je zaključil, da so koristi kombiniranih hormonskih kontraceptivov pri preprečevanju neželenih nosečnosti še vedno večje od z njimi povezanih tveganj in da je dobro znano tveganje za VTE pri vseh teh kontraceptivih majhno.
A review of the data was first conducted by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations. 
Pregled podatkov je najprej opravil Odbor za oceno tveganja na področju farmakovigilance (PRAC), torej odbor, odgovoren za presojo varnostnih vprašanj o zdravilih za uporabo v humani medicini, ki je podal več priporočil.
The review also looked at the risk of arterial thromboembolism (ATE, blood clots in arteries, which can potentially cause a stroke or heart attack). 
Med pregledom so proučili tudi tveganje za arterijsko tromboembolijo (ATE, tj. nastajanje krvnih strdkov v arterijah, ki lahko povzročijo možgansko ali srčno kap).
• If you have been taking CHCs without any problem, there is no reason for you to stop taking them on the basis of this review. 
• Če med jemanjem kombiniranih hormonskih kontraceptivov niste imeli težav, ni nobenega razloga, da bi jih zaradi tega pregleda nehali jemati.
The PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for all questions concerning medicines for human use, which adopted the Agency's final opinion. 
Priporočila je posredoval Odboru za zdravila za uporabo v humani medicini (CHMP), pristojnemu za vsa vprašanja, povezana z zdravili za uporabo v humani medicini, ki je sprejel končno mnenje agencije.
The CHMP opinion, in agreement with the previous recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC), was sent to the European Commission, which adopted on 16 January 2014 a legally binding decision to update the product information of all CHCs throughout the EU. 
Mnenje odbora CHMP, ki se je ujemalo s predhodnim priporočilom Odbora za oceno tveganja na področju farmakovigilance (PRAC), je bilo posredovano Evropski komisiji, ki je dne 16. januarja 2014 sprejela pravno zavezujoči sklep, v skladu s katerim je treba posodobiti informacije o zdravilu za vse kombinirane hormonske kontraceptive po vsej EU.
The review included all contraceptives containing low-dose oestrogen and the following progestogens: chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin and norgestimate. 
V pregled so bili vključeni vsi kontraceptivi, ki vsebujejo nizkoodmerni estrogen in naslednje progestogene: klormadinon, dezogestrel, dienogest, drospirenon, etonogestrel, gestoden, nomegestrol, norelgestromin in norgestimat.
On 21 November 2013, the European Medicines Agency completed its review of combined hormonal contraceptives (CHCs), particularly of the risk of venous thromboembolism (VTE or blood clots in veins) associated with their use. 
Evropska agencija za zdravila je dne 21. novembra 2013 zaključila pregled kombiniranih hormonskih kontraceptivov, zlasti tveganja za vensko trombembolijo (VTE, tj. nastajanja krvnih strdkov v venah), povezanega z njihovo uporabo.
• This Europe-wide review looked at the benefits and risks of combined hormonal contraceptives (CHCs), particularly the risk of blood clots associated with these medicines. 
• V tem pregledu, ki je potekal na evropski ravni, so bile proučene koristi in tveganja kombiniranih hormonskih kontraceptivov, zlasti tveganje za nastanek krvnih strdkov, povezano s temi zdravili.
• The EU-wide review of combined hormonal contraceptives (CHCs) has confirmed that the known risk of venous thromboembolism (VTE) with all low-dose CHCs (ethinylestradiol < 50 mcg) is small. 
• Pregled kombiniranih hormonskih kontraceptivov v EU je potrdil, da je znano tveganje za vensko trombembolijo (VTE) pri vseh nizkoodmernih kombiniranih hormonskih kontraceptivih (etinilestradiol < 50 µg) majhno.
CHCs contain two types of hormones, an oestrogen and a progestogen. 
Kombinirani hormonski kontraceptivi vsebujejo dve vrsti hormonov, estrogen in progestogen.
It confirmed that the benefits of CHCs outweigh the risk of blood clots, which has been known for many years and is very low. 
Pregled je potrdil, da so koristi kombiniranih hormonskih kontraceptivov večje od tveganja za pojav krvnih strdkov, ki je dobro znano že več let in je zelo majhno.